173 related articles for article (PubMed ID: 30765384)
1. Determinants of inter-practice variation in ADHD diagnosis and stimulant prescribing: cross-sectional database study of a national surveillance network.
Hoang U; James AC; Liyanage H; Jones S; Joy M; Blair M; Rigby M; Lusignan S
BMJ Evid Based Med; 2019 Aug; 24(4):155-161. PubMed ID: 30765384
[TBL] [Abstract][Full Text] [Related]
2. Physician practices to prevent ADHD stimulant diversion and misuse.
Colaneri N; Keim S; Adesman A
J Subst Abuse Treat; 2017 Mar; 74():26-34. PubMed ID: 28132697
[TBL] [Abstract][Full Text] [Related]
3. Physician perceptions of the use of medications for attention deficit hyperactivity disorder.
Stockl KM; Hughes TE; Jarrar MA; Secnik K; Perwien AR
J Manag Care Pharm; 2003; 9(5):416-23. PubMed ID: 14613439
[TBL] [Abstract][Full Text] [Related]
4. Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD.
Patel A; Medhekar R; Ochoa-Perez M; Aparasu RR; Chan W; Sherer JT; Alonzo J; Chen H
Psychiatr Serv; 2017 Jul; 68(7):681-688. PubMed ID: 28196459
[TBL] [Abstract][Full Text] [Related]
5. Common Use of Stimulants and Alpha-2 Agonists to Treat Preschool Attention-Deficit Hyperactivity Disorder: A DBPNet Study.
Blum NJ; Shults J; Harstad E; Wiley S; Augustyn M; Meinzen-Derr JK; Wolraich ML; Barbaresi WJ
J Dev Behav Pediatr; 2018 Sep; 39(7):531-537. PubMed ID: 29851669
[TBL] [Abstract][Full Text] [Related]
6. Social adversity and regional differences in prescribing of ADHD medication for school-age children.
Wallach-Kildemoes H; Skovgaard AM; Thielen K; Pottegård A; Mortensen LH
J Dev Behav Pediatr; 2015 Jun; 36(5):330-41. PubMed ID: 25997081
[TBL] [Abstract][Full Text] [Related]
7. Co-morbidity and patterns of care in stimulant-treated children with ADHD in the Netherlands.
Faber A; Kalverdijk LJ; de Jong-van den Berg LT; Hugtenburg JG; Minderaa RB; Tobi H
Eur Child Adolesc Psychiatry; 2010 Feb; 19(2):159-66. PubMed ID: 19894075
[TBL] [Abstract][Full Text] [Related]
8. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
[TBL] [Abstract][Full Text] [Related]
9. Young Children with Attention-Deficit/Hyperactivity Disorder and/or Disruptive Behavior Disorders Are More Frequently Prescribed Alpha Agonists Than Stimulants.
Mittal S; Boan AD; Kral MC; Lally MD; van Bakergem K; Macias MM; LaRosa A
J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):81-86. PubMed ID: 31621385
[No Abstract] [Full Text] [Related]
10. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
Goldman LS; Genel M; Bezman RJ; Slanetz PJ
JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
[TBL] [Abstract][Full Text] [Related]
11. Influence of Age, Gender, and Living Circumstances on Patterns of Attention-Deficit/Hyperactivity Disorder Medication Use in Children and Adolescents With or Without Intellectual Disabilities.
Osunsanmi S; Turk J
J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):828-834. PubMed ID: 26982546
[TBL] [Abstract][Full Text] [Related]
12. Variations in Physician Attitudes Regarding ADHD and Their Association With Prescribing Practices.
Sheldrick RC; Leslie LK; Rodday AM; Parsons SK; Saunders TS; Wong JB
J Atten Disord; 2015 Jul; 19(7):569-77. PubMed ID: 23142852
[TBL] [Abstract][Full Text] [Related]
13. Physician Office Visits for Attention-deficit/Hyperactivity Disorder in Children and Adolescents Aged 4-17 Years: United States, 2012-2013.
Albert M; Rui P; Ashman JJ
NCHS Data Brief; 2017 Jan; (269):1-8. PubMed ID: 28135186
[TBL] [Abstract][Full Text] [Related]
14. Current Australian pediatric practice in the assessment and treatment of ADHD.
Efron D; Davies S; Sciberras E
Acad Pediatr; 2013; 13(4):328-33. PubMed ID: 23830018
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for incident attention-deficit/hyperactivity disorder: practice patterns and quality metrics.
Bussing R; Narwaney KJ; Winterstein AG; Newton DA; DeBar L; Boscarino JA; Toh S; Pawloski P; Nordin JD; Herrinton LJ; Mason D; Daley MF
Curr Med Res Opin; 2014 Aug; 30(8):1687-99. PubMed ID: 24635013
[TBL] [Abstract][Full Text] [Related]
16. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
[TBL] [Abstract][Full Text] [Related]
17. Age, academic performance, and stimulant prescribing for ADHD: a nationwide cohort study.
Zoëga H; Valdimarsdóttir UA; Hernández-Díaz S
Pediatrics; 2012 Dec; 130(6):1012-8. PubMed ID: 23166340
[TBL] [Abstract][Full Text] [Related]
18. Gender and injuries predict stimulant medication use.
Dalsgaard S; Leckman JF; Nielsen HS; Simonsen M
J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):253-9. PubMed ID: 24813570
[TBL] [Abstract][Full Text] [Related]
19. Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015.
Mac Avin M; Teeling M; Bennett KE
BMJ Open; 2020 Apr; 10(4):e035716. PubMed ID: 32327478
[TBL] [Abstract][Full Text] [Related]
20. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
McCarthy S; Wilton L; Murray ML; Hodgkins P; Asherson P; Wong IC
BMC Pediatr; 2012 Jun; 12():78. PubMed ID: 22712630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
